目的 探討?zhàn)B血清腦顆粒聯(lián)合艾地苯醌治療血管性癡呆的臨床療效。方法 選取2018年1月-2019年12月在河南省榮軍醫(yī)院治療的血管性癡呆患者90例，隨機分為對照組（45例）和治療組（45例）。對照組飯后口服艾地苯醌片，1片/次，3次/d。治療組在對照組的基礎(chǔ)上口服養(yǎng)血清腦顆粒，1袋/次，3次/d。兩組患者連續(xù)治療60 d。觀察兩組患者臨床療效，同時比較治療前后兩組患者簡易智能精神狀態(tài)量表（MMSE）和日常生活能力量表（ADL）評分，及血清丙二醛（MDA）、超氧化物歧化酶（SOD）和腦源性神經(jīng)營養(yǎng)因子（BDNF）水平。結(jié)果 治療后，對照組和治療組臨床有效率分別為77.78%和93.33%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者MMSE、ADL評分顯著上升（P<0.05），且治療組明顯高于對照組（P<0.05）。治療后，兩組患者血清MDA水平顯著下降（P<0.05），SOD、BDNF水平顯著上升（P<0.05），且治療組改善情況明顯好于對照組（P<0.05）。結(jié)論 養(yǎng)血清腦顆粒聯(lián)合艾地苯醌治療血管性癡呆療效確切，促進患者認(rèn)知功能和生活能力改善，保護神經(jīng)元，減輕氧化應(yīng)激反應(yīng)。

Objective To explore the clinical effect of Yangxue Qingnao Granules combined with idebenone in treatment of vascular dementia. Methods Patients (90 cases) with vascular dementia in Henan Rongjun Hospital from January 2018 to December 2019 were randomly divided into control (45 cases) and treatment (45 cases) groups. Patients in the control group were po administered with Idebenone Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Yangxue Qingnao Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 60 d. After treatment, the clinical efficacy was evaluated, and the MMSE and ADL scores, the serum levels of MDA, SOD and BDNF in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 77.78% and 93.33% respectively, and there were differences between two groups (P<0.05). After treatment, the MMSE and ADL scores in two groups were significantly increased (P<0.05), and which in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum levels of MDA in two groups were significantly decreased (P<0.05), but the SOD and BDNF levels in two groups were significantly increased (P<0.05), and these indicators in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Yangxue Qingnao Granules combined with idebenone has a significant clinical effect on vascular dementia, can improve the cognitive function and the ability of daily life, protect neurons, and reduce oxidative stress.

R971